LONDON, Nov. 14, 2016 /PRNewswire/ -- The global plasma fractionation market is estimated to grow at a CAGR of 6.7% from 2016 to 2021, to reach USD 26.07 billion by 2021 from USD 18.84 billion in 2016. Growth in this market is mainly attributed to growing aging population, rising incidences of bleeding and immune disorders, and growing use of immunoglobulin and alpha-1-antitrypsin. However, the high cost of plasma products, adverse reactions associated with use of products, and limited reimbursement policies can hinder the growth of this market. Moreover, the increasing usage of recombinant coagulation factors as an alternative to plasma-derived coagulation factors is further hampering the growth of this market to a certain extent. In this report, the plasma fractionation market is segmented on the basis of products, applications, end users, and regions. In 2015, the immunoglobulin segment accounted for the largest share of the global plasma fractionation market, by product. The large share of this segment can primarily be attributed to the rising incidences of neurological and immunological diseases, growing use of intravenous immunoglobulin (IVIg) in various therapeutic areas, and rising adoption of subcutaneous immunoglobulin (SCIg). On the basis of application, neurology segment accounted for the largest share of the plasma fractionation market. In 2015, hospitals and clinics accounted for the largest share of global plasma fractionation market, by end-user. This large share for hospitals and clinics is due to increasing use of plasma products for labeled and off-labeled use for the treatment of various diseases in hospitals and clinics. In addition, the improvement of healthcare infrastructure in hospitals and clinics in emerging countries is expected to support the growth of this segment. Geographically, North America commanded a major share of the plasma fractionation market in 2015. However, Asia-Pacific is expected to witness the highest growth rate during the forecast period. Growth in the Asia-Pacific market can be attributed to the rapid growth in the aging population, increasing use of albumin and immunoglobulin, and increasing number of hemophilic patients. Some of the prominent players in the plasma fractionation market include CSL Ltd. ( Australia), Grifols S.A ( Spain), Baxalta Incorporated (U.S.), Octapharma AG ( Switzerland), Kedrion S.p.A ( Italy), China Biologic Products, Inc. ( China), Biotest AG ( Germany), LFB S.A ( France), Bio Product Laboratory Ltd. (U.K.), and Sanquin ( Netherlands). Reasons to Buy the Report: The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms in garnering greater market shares. Firms purchasing the report could use any one or combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for increasing their market shares.